Ontario Teachers Pension Plan Board lessened its stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 35.4% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 9,504 shares of the medical research company’s stock after selling 5,199 shares during the period. Ontario Teachers Pension Plan Board’s holdings in Amgen were worth $2,702,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds have also recently modified their holdings of the stock. Provence Wealth Management Group raised its holdings in Amgen by 11.9% in the 4th quarter. Provence Wealth Management Group now owns 1,445 shares of the medical research company’s stock valued at $416,000 after acquiring an additional 154 shares during the last quarter. Kinsale Capital Group Inc. raised its holdings in Amgen by 33.0% in the 4th quarter. Kinsale Capital Group Inc. now owns 11,348 shares of the medical research company’s stock valued at $3,269,000 after acquiring an additional 2,814 shares during the last quarter. Global Wealth Management Investment Advisory Inc. raised its holdings in Amgen by 2.4% in the 4th quarter. Global Wealth Management Investment Advisory Inc. now owns 4,733 shares of the medical research company’s stock valued at $1,363,000 after acquiring an additional 109 shares during the last quarter. Traynor Capital Management Inc. raised its holdings in Amgen by 9.5% in the 4th quarter. Traynor Capital Management Inc. now owns 18,941 shares of the medical research company’s stock valued at $5,455,000 after acquiring an additional 1,650 shares during the last quarter. Finally, Valley Brook Capital Group Inc. raised its holdings in Amgen by 7.0% in the 4th quarter. Valley Brook Capital Group Inc. now owns 4,730 shares of the medical research company’s stock valued at $1,362,000 after acquiring an additional 310 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.
Insider Activity
In other news, SVP Nancy A. Grygiel sold 2,117 shares of the firm’s stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $313.09, for a total value of $662,811.53. Following the sale, the senior vice president now directly owns 9,883 shares in the company, valued at approximately $3,094,268.47. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.69% of the company’s stock.
Wall Street Analyst Weigh In
Check Out Our Latest Research Report on Amgen
Amgen Stock Up 1.4 %
AMGN stock traded up $4.68 during midday trading on Monday, hitting $335.97. The company’s stock had a trading volume of 1,681,452 shares, compared to its average volume of 2,680,763. The company has a quick ratio of 0.98, a current ratio of 1.42 and a debt-to-equity ratio of 11.96. Amgen Inc. has a 52-week low of $228.21 and a 52-week high of $338.98. The firm has a market capitalization of $180.22 billion, a P/E ratio of 47.33, a PEG ratio of 3.00 and a beta of 0.58. The firm has a 50-day simple moving average of $311.81 and a 200-day simple moving average of $296.22.
Amgen (NASDAQ:AMGN – Get Free Report) last issued its quarterly earnings results on Thursday, May 2nd. The medical research company reported $3.96 EPS for the quarter, beating the consensus estimate of $3.76 by $0.20. Amgen had a net margin of 12.74% and a return on equity of 156.21%. The company had revenue of $7.45 billion during the quarter, compared to analysts’ expectations of $7.45 billion. During the same quarter last year, the company posted $3.98 EPS. The firm’s revenue was up 22.0% compared to the same quarter last year. As a group, equities analysts forecast that Amgen Inc. will post 19.48 EPS for the current year.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
See Also
- Five stocks we like better than Amgen
- The 3 Best Fintech Stocks to Buy Now
- Intuitive Surgical Stock Outperforms Market: Highs on the Horizon
- Pros And Cons Of Monthly Dividend Stocks
- Has This Leading Tech Stock Halted the AI Surge?
- Top Biotech Stocks: Exploring Innovation Opportunities
- Revolutionary Battery Stock Gains Momentum with 3D Silicon-Anodes
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.